Press Releases

Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy.  Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need. Seattle and Vancouver, British Columbia, June 26, 2025  — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company…

Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone. If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades.  More than 2,000 clinical trial participants contributed to the body of evidence submitted in the NDA demonstrating cytisinicline’s…

SEATTLE and VANCOUVER, British Columbia, May 28, 2025 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will present at the Jefferies Global Healthcare Conference being held June 3–5,…

Oral Presentation to Highlight Key Benefits of Cytisinicline’s Dual Mechanism of Action to Pulmonary Specialists. SEATTLE and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today…

Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025. Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025. SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and…